tbuckley/cabot-search huggingface dataset:
The Treatment of Mild Hypertension Study
Authors: Edward B. Nelson
Journal: JAMA (1993)

<h3>To the Editor.</h3> —The Treatment of Mild Hypertension Study (TOMHS)<sup>1</sup>represents a worthy contribution to the evaluation of therapeutic interventions on outcomes in patients with mild hypertension. The use of broad categories of morbidity and mortality outcomes demonstrated the overall benefit of antihypertensive agents plus lifestyle modification compared with lifestyle modification alone. Blood pressure reductions with all five antihypertensive agents (acebutolol, amlodipine maleate, chlorthalidone, doxazosin mesylate, and enalapril maleate) plus lifestyle modification were significantly greater than with lifestyle modification alone for "all follow-up BP [blood pressure] measurements." The significance of blood pressure reduction was also addressed in the accompanying Editorial<sup>2</sup>stating, "All classes of drugs, with the exception of the angiotensin-converting enzyme inhibitor (enalapril), were equally effective in lowering blood pressure in TOMHS and all were superior to the lifestyle-modification regimen given with placebo." Clarification of this statement is needed because the drug dosages evaluated in TOMHS were
Book Listings
Journal: Annals of Internal Medicine (2002)

Book Listings5 November 2002Book ListingsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-9-200211050-00037 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail CardiologyAlcohol and Heart DiseaseR Watson and AK Myers, eds. 261 pages. Philadelphia: Taylor & Francis; 2002. $80.00. ISBN 0415273471. Order phone 800-821-8312.Beta-Blockers in Heart FailureJ McMurray and MJ Kendall. 108 pages. Philadelphia: Taylor & Francis; 2002. $15.00. ISBN 1853179027. Order phone 800-821-8312.Blackwell's Primary Care Essentials: CardiologyJ Sutherland. 304 pages. Cambridge, MA: Blackwell Science; 2001. $40.00. ISBN 0632044756. Order phone 800-759-6102.Cardiac Arrythmias: Practical Notes on Interpretation and Treatment6th edition. DH Bennett. 340 pages. Boston: Arnold; 2002. $30.00. ISBN 0340807318. Order phone 800-759-6102.Cardiogenic Shock: Diagnosis and TreatmentD Hasdai, PB Berger, A Battler, and DR Holmes Jr, eds. ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2002Volume 137, Issue 9Page: B1 ePublished: 5 November 2002 Issue Published: 5 November 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.Loading ...
First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).
Authors: Jacob M. Sands, Toshio Shimizu, Edward B. Garon, Jonathan Greenberg, Rebecca Suk Heist, Fumiaki Kobayashi, Yutaka Noguchi, Daisuke Okajima, Alexander I. Spira, Noboru Yamamoto, Tomonari Yamashita, Aaron Elliott Lisberg
Journal: Journal of Clinical Oncology (2018)

TPS2605 Background: DS-1062a is a trophoblast cell-surface antigen 2 (TROP2)-targeting antibody drug conjugate. TROP2 is overexpressed in epithelial cancers, including non-small cell lung cancer (NSCLC), and its overexpression is associated with poor survival in solid tumors. In preclinical studies, DS-1062a showed promising antitumor activity and an acceptable safety profile in TROP2-positive tumors with a long half-life, allowing for every-3-week (Q3W) dosing. This dose escalation (ESC) and dose expansion (EXP) study will investigate DS-1062a in pts with ASTs (NCT03401385). Primary objectives are to determine the maximum tolerated dose and recommended dose for expansion (RDE) based on the dose limiting toxicity (DLT) rate (ESC) and assess safety and tolerability (ESC + EXP). Secondary objectives include pharmacokinetics (PK), antitumor activity and anti-drug antibody (ADA) incidence. Methods: In this multicenter, open-label study in the US and Japan, pts aged ≥18 (US) or ≥20 (Japan) years with unresectable relapsed or refractory advanced NSCLC are eligible regardless of TROP2 expression; other ASTs may be included if safety and efficacy in NSCLC is demonstrated. In ESC, initial intravenous DS-1062a infusion will start at 0.27 mg/kg, followed by 21-day observation. Subsequent doses will be given Q3W. In EXP, pts will receive RDE Q3W. Pts will be treated until unacceptable toxicity, progressive disease, consent withdrawal or death. Endpoints include DLTs, adverse events (safety) and tumor response evaluated using RECIST v1.1 (efficacy). Pre-, on- and post-treatment tumor samples will be evaluated for TROP2 expression and other biomarker analyses. Immunogenicity will be assessed via ADA incidence and titer. Population PK and exposure-response analysis will be conducted. Pts will be enrolled in ESC using a modified continuous reassessment method and dose escalation with overdose control, with at least 3 DLT-evaluable pts per dose level. For EXP, 40 pts with NSCLC and up to 40 pts with other solid tumors will be enrolled. Enrollment is open. Clinical trial information: NCT03401385.
Case Recorder in General Medicine and Gynecology; for the Use of Physicians, Students, Dispensaries and Hospitals.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Right upper quadrant gas shadows
Authors: C. A. Beetlestone
Journal: JAMA (1976)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intracranial Metastases
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Specialties, and Their Ethical Relations.
Journal: JAMA (1883)

—Twice, within a short time, has the editor of this journal been applied to for information (and many other times in years past) in regard to the questions, "<i>How far, and in what way</i>, can those members of the profession who are desirous of pursuing a special practice, or, in other words, limiting their practice to certain diseases or the affections of certain organs, make known their position by cards or advertisements without violating the National Code of Ethics?" The highly intelligent sources from which these inquiries have come, render it probable that only a small number in the profession know the answers that have been given at different times by direct action of the American Medical Association. It is well known that the National Code of Ethics contains no allusion to<i>specialties</i>, in the sense that the word is now used, but simply declares it to be " derogatory to
Flexner
Authors: Janet A. Tighe
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial
Authors: H. Riess, U. Pelzer, G. Deutschinoff, B. Opitz, M. Stauch, P. Reitzig, S. Hahnfeld, A. Hilbig, J. Stieler, H. Oettle
Journal: Journal of Clinical Oncology (2009)

LBA4506 Background: The course of pts with APC is often complicated by venous thromboembolic events (VTE). Anticoagulation therapy with LMWH may prevent VTE and is under discussion to improve overall survival (OS) in cancer. Based on our previous pilot study (Hilbig et al, Onkologie 2005;28(suppl 3)) indicating the safety and feasibility to the addition of the LMWH enoxaparin to chemotherapy in pts with APC we started the open, prospective, randomized, multicenter study to investigate the role of enoxaparin in these pts. Methods: Primary endpoint was the reduction of symptomatic VTE (sVTE) from an expected 10% to 3% within the first 12 weeks of treatment. The occurrence of sVTE (secured by an independent, blinded event review board) in 24 pts was calculated to be necessary in order to define the role of enoxaparin in decreasing the risk of VTE. Toxicity, time to progression (TTP), and OS were among the secondary endpoints of the study approved by the ethics committees of the participating centers. VTE-naive and chemotherapy-naive pts with histologically or cytologically confirmed APC were randomized to receive or not to receive additional LMWH (enoxaparin 1mg/kg once daily) starting in parallel to palliative systemic chemotherapy. Results: In January 2009 after recruitment of 312 pts the study was closed. There were 22 sVTE in 152 pts of the observation group (O) and 8 in 160 pts of the enoxaparin group (E). ITT and PP analyses demonstrated significant risk reductions from 14.5% to 5.0% (65% RRR) and 14.5% to 3.8% (74% RRR) for E, respectively. Major bleeding events were 9.9% for O and 6.3% for E (ITT; n.s.). In each group there was one tumor-related fatal hemorrhage. Preliminary data show no difference in TTP (O:19 vs. E:22 w) and OS (O:29 vs. E:31 w). Conclusions: Enoxaparin is effective and safe in the primary prevention of sVTE applied in parallel with cytotoxic chemotherapy in pts with APC. Final results on TTP and OS are pending. No significant financial relationships to disclose.
THE INTERPRETATION OF MEDICAL LABORATORY FINDINGS.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1958)

COMMITTEE ON MATERNAL WELFARESpontaneous Rupture of the Uterus Due to Transverse Presentation and Low-Lying Placental ImplantationA twenty-three-year-old gravida 4, para 2, with known aortic stenosis for four years, had been asymptomatic during 2 full-term pregnancies and 1 early miscarriage. The current prenatal course had been uneventful except for a rising titer of antibodies to the Rh factor.The patient was admitted at term with ruptured membranes and a transverse presentation. There was no bleeding. The presentation could be converted to cephalic by external pressure, but malposition always recurred. X-ray examination failed to demonstrate the placenta. On the tenth . . .
Nutritional Support
Authors: Wiley W. Souba
Journal: New England Journal of Medicine (1997)

The indications for providing nutrients by the enteral or intravenous route (nutritional support) are not well defined, and the efficacy of nutritional support in many circumstances is unproved. Nonetheless, nutritional support is widely used for several reasons: malnutrition is common in hospitalized patients,1,2 there is an association between malnutrition and increased morbidity3,4 and mortality,5 it seems intuitively likely that well-nourished patients will respond most favorably to treatment, nutritional support can be administered safely to most patients, and clinical trials indicate that it is beneficial in selected patients.610 Virtually all patients can be fed intravenously or enterally, because . . .
Textbook of Paediatrics
Authors: N. B. Capon
Journal: BMJ (1951)

Patients with duodenal ulcer disease received either a two hour pentagastrin infusion test or a similar test with the addition of a bolus of cimetidine, 200 mg, after one hour of pentagastrin. Pentagastrin induced secretion of acid and histamine, the secretion patterns of the two being similar. Total histamine output in the gastric aspirate in the first hour of pentagastrin infusion was related to total acid output (r = 0.58, p less than 0.01). A similar correlation was observed during the second hour of pentagastrin infusion (r = 0.61, p less than 0.05). Plasma histamine concentration rose to a peak coinciding with maximal acid secretion. After cimetidine blockade, gastric acid fell rapidly but gastric histamine output did not change. Plasma histamine concentration increased further. These results suggest that pentagastrin induced gastric histamine release is not affected by an acid inhibiting dose of cimetidine. Cimetidine caused histamine release into the circulation in both healthy volunteers and patients after total gastrectomy. The rise in plasma histamine concentration, however, was transient. In contrast, during pentagastrin infusion, the plasma histamine concentration remained high. These data support the hypothesis that histamine release induced by pentagastrin is a major stimulant of gastric acid secretion.
Injuries to Joints.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blood resource management
Authors: J. B. Henry
Journal: JAMA (1979)

THE RISK of posttransfusion hepatitis associated with blood from compensated donors is estimated to be from three to ten times greater than that from blood given by volunteer donors. Anywhere from 10,000 to 30,000 cases of overt hepatitis occur each year as a result of blood transfusion. Further, there may be as many as 100,000 subclinical cases that go unreported. Citing the lifethreatening hazard that accompanies the use of blood from paid donors, the Food and Drug Administration in 1978 published a regulation requiring that blood be distinguished by source. Prominently marked labels bearing the statement "volunteer donor" or "paid donor" now must appear on each container of whole blood or components intended for transfusion. At the same time, limits on the capability of detecting viral hepatitis in donor blood suggest that the disease will continue to be transmitted through transfusion. Thus, while hepatitis remains a problem of no small
The Cognitive Origins of Specific Types of Schizophrenic Speech Disturbances
Authors: Nancy Docherty
Journal: American Journal of Psychiatry (2006)

Objective: Cognitive impairments associated with schizophrenia might be expected to have a marked impact on the ability to produce coherent speech, yet associations between cognitive performance and speech disorder have typically been weak. Findings on this question may have been limited by measurement methods and by the heterogeneity of speech disorder. This study examined the contributions of impairments in sustained attention and sequencing abilities to schizophrenic speech disorder, measured in terms of communication failures and divided into different types of disorder. Method: Samples of natural speech were collected from severely ill inpatients with schizophrenia and nonpsychiatric comparison subjects and rated for frequencies of six types of communication failures: four structural and two nonstructural types. Subjects also completed a battery of cognitive tests assessing several facets of attention and sequencing ability. Hierarchical regression was used to identify cognitive contributors to communication failures. Results: Impaired sustained attention was associated with more frequent structural and nonstructural communication failures. As predicted, impaired sequencing, and in particular conceptual sequencing, also made a substantial contribution to the structural communication failures, but not to the nonstructural ones. These findings held when global level of impairment was controlled statistically. Performance on the tests of attention and sequencing explained 56% of the variance in structural speech disorder. Conclusions: Schizophrenic speech disorder is heterogeneous in form and in cognitive underpinnings. Impairments in attention and sequencing abilities are highly predictive of communication failures related to language structure.
OA03.04 Analysis of Patient Microbiome and Its Correlation to Immunotherapy Response and Toxicity in Lung Cancer
Authors: J. Chau, M. Yadav, M. Furqan, N. Cady, K. Nace Mercer, E. Eastman, T. Abu-Hejleh, S. Shahi, Q. Dai, Y. Zakharia, R. Garje, C. Chan, G. Weiner, A. Mangalam, J. Zhang
Journal: Journal of Thoracic Oncology (2019)
Prevalence and Determinants of Lead Intoxication in Mexican Children of Low Socioeconomic Status
Authors: Lizbeth Lopez-Carrillo, Luisa Torres-Sanchez, Francisco Garrido, Joaquin Papaqui-Hernandez, Eduardo Palazuelos-Rendon, Malaquias Lopez-Cervantes
Journal: Environmental Health Perspectives (1996)

orts on the prvaence of lead poiso in
Sarcoidosis
Authors: C J Johns, P P Scott, S A Schonfeld
Journal: Annual Review of Medicine (1989)

Sarcoidosis continues to be a disease defined descriptively rather than by etiology. Bronchoalveolar lavage has brought new understandings of the pulmonary inflammatory process and its pathogenesis and defects in immunoregulation. Much is known of the clinical characteristics of sarcoidosis, its diagnosis and management. Spontaneous remissions are common, but when treatment is required, the response to corticosteroids is often dramatic, although long-term treatment may be required. The appropriate use of corticosteroids is discussed fully, as are special clinical problems.